0001845314-21-000001.txt : 20210217 0001845314-21-000001.hdr.sgml : 20210217 20210216185401 ACCESSION NUMBER: 0001845314-21-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210217 DATE AS OF CHANGE: 20210216 EFFECTIVENESS DATE: 20210217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunoRx Pharma, Inc. CENTRAL INDEX KEY: 0001845314 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-389613 FILM NUMBER: 21641786 BUSINESS ADDRESS: STREET 1: 1000 N. WEST ST., SUITE 1200 CITY: WILMINGTON STATE: DE ZIP: 19801 BUSINESS PHONE: 6493324417 MAIL ADDRESS: STREET 1: 1000 N. WEST ST., SUITE 1200 CITY: WILMINGTON STATE: DE ZIP: 19801 D 1 primary_doc.xml X0708 D LIVE 0001845314 ImmunoRx Pharma, Inc. 1000 N. WEST ST., SUITE 1200 WILMINGTON DE DELAWARE 19801 6493324417 DELAWARE None None Corporation true 2020 Caroline Fortier 1000 N. West St., Suite 1200 Wilmington DE DELAWARE 19801 Executive Officer Mark Cipriano 1000 N. West St., Suite 1200 Wilmington DE DELAWARE 19801 Executive Officer Marc Riviere 2 Place Alexis Nihon, Suite 902 3500 Blvd de Maisonneuve West Westmount A8 QUEBEC, CANADA H3Z 3C1 Director Philippe Tessier 1040 Rue Pierre-Perrault #325 Lewis A8 QUEBEC, CANADA G7A 0Z8 Director Alexandre Lebeaut 1302 Wakefield Ct. Southlake TX TEXAS 76092 Director Pharmaceuticals Decline to Disclose 06b false 2020-11-26 false true false 0 25437000 2667000 22770000 This offering was made in exchange for (i) $24.77M in total possible cash consideration in five tranches based on developmental milestones and (ii) certain licensing rights to investor's proprietary compound, which were estimated to be valued at $667,000. false 2 0 0 86000 true The offering is structured in five tranches of financing, contingent on issuer meeting specific developmental milestones. If the total financing amount is achieved, executive officers and directors will be paid up to $1.2M. false ImmunoRx Pharma, Inc. Juan Felipe Velasquez Juan Felipe Velasquez Attorney-in-Fact for Caroline Fortier, CEO 2021-02-16